A129 CYP2C19 PHARMACOGENETIC TESTING IN PAEDIATRIC PATIENTS WITH EOSINOPHILIC ESOPHAGITIS INFLUENCES DOSING OF PROTON-PUMP-INHIBITORS AND RESPONSE TO THERAPY

BACKGROUND: Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder that can be treated with a proton pump inhibitor (PPI). Pharmacogenetics (PGx) is the study of how variations in an individual’s genome influences drug response. Genetic variation in the metabolism gene CYP2C19 can produce...

Descripción completa

Detalles Bibliográficos
Autores principales: Bortolin, K A, Cohn, I, Da Silva, S, Ito, S, Marcon, P, Afzal, N, Scodellaro, S, Verstegen, R, Hulst, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Poster of Distinction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859342/
http://dx.doi.org/10.1093/jcag/gwab049.128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859342/
http://dx.doi.org/10.1093/jcag/gwab049.128

Ejemplares similares